KR20060005356A - 탄닌과 배합된 락토바실러스 플랜타룸 스트레인을 포함하는조성물 및 락토바실러스 플랜타룸 스트레인 - Google Patents
탄닌과 배합된 락토바실러스 플랜타룸 스트레인을 포함하는조성물 및 락토바실러스 플랜타룸 스트레인 Download PDFInfo
- Publication number
- KR20060005356A KR20060005356A KR1020057018900A KR20057018900A KR20060005356A KR 20060005356 A KR20060005356 A KR 20060005356A KR 1020057018900 A KR1020057018900 A KR 1020057018900A KR 20057018900 A KR20057018900 A KR 20057018900A KR 20060005356 A KR20060005356 A KR 20060005356A
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus plantarum
- tanase
- dsm
- lactobacillus
- strains
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 60
- 229920001864 tannin Polymers 0.000 title claims abstract description 50
- 235000018553 tannin Nutrition 0.000 title claims abstract description 50
- 239000001648 tannin Substances 0.000 title claims abstract description 50
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 43
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 241000186660 Lactobacillus Species 0.000 claims abstract description 37
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 30
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000009920 food preservation Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 108010038851 tannase Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 19
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229920002770 condensed tannin Polymers 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000252983 Caecum Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 241000219094 Vitaceae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000021021 grapes Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SFWZZSXCWQTORH-UHFFFAOYSA-N 1-methyl-2-phenylindole Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=CC=CC=C1 SFWZZSXCWQTORH-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000207836 Olea <angiosperm> Species 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 235000021019 cranberries Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 229920001461 hydrolysable tannin Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PJPOCNJHYFUPCE-UHFFFAOYSA-N picen-1-ol Chemical compound C1=CC=CC2=C(C=CC=3C4=CC=C5C=CC=C(C=35)O)C4=CC=C21 PJPOCNJHYFUPCE-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000021013 raspberries Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical class OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000008299 Pinus lambertiana Species 0.000 description 1
- 235000008595 Pinus lambertiana Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 239000001975 Violet Red Bile Dextrose Agar Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 235000004458 antinutrient Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/0102—Tannase (3.1.1.20)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/857—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
생물체 | 스트레인 | 탄나아제 활성 * (양성 또는 음성) | 정량적 탄나아제 활성 ** (A440/A620) |
락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 | 299v DSM 9843 LP2 LP5 4LF:1 17LF:1 HEAL 9 DSM 15312 HEAL 19 DSM 15313 HEAL 99 DSM 15316 | + + + + + + + + | 6.2 4.9 3.3 6.1 5.4 6.4 7.4 6.8 |
유기체 | 스트레인 | HT-29 세포로의 부착(세포당 박테리아의 수) | |
염 용액 중 | 메틸만노시드의 존재시 | ||
락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 락토바실러스 플랜타룸 | 299v DSM 9843 HEAL 9 HEAL 99 HEAL 19 ATCC 14917T 78B | 11.7 20 20 23 5.2 0.3 | 3.4 2.1 2.0 5.0 2.2 0.5 |
마우스 그룹 | 결장 조직 g 당 말론디알데하이드(MDA) [중앙값] |
G1. 대조군 A; 비손상 (허혈/재관류 없음); 정상 식품 G2. 대조군 B; 정상 식품 G3. 정상 식품+로즈힙 분말(RHP) G4. 정상 식품+L. 플랜타룸 299v G5. 정상 식품+RHP+L. 플랜타룸 299v | 4.3 6.3 5.1 5.8 3.6 |
마우스 | 육안 계수의 중앙값 (맹장 함량 g 당 CFU) | |||
총 혐기성 생물 | 총 호기성 생물 | 락토바실러스 | 엔테로박테리아세 | |
G1. 대조군 A; 비손상 (허혈/재관류 없음); 정상 식품 G2. 대조군 B; 정상 식품 G3. 정상 식품+로즈힙 분말(RHP) G4. 정상 식품+L. 플랜타룸 299v G5. 정상 식품+RHP+L. 플랜타룸 299v | 2×108 3×109 1×108 3×109 4×109 | 1×108 1×109 4×108 4×109 2×109 | 5×108 1×109 1×108 2×109 3×109 | 3×103 4×103 <102 3×103 <102 |
Claims (14)
- 탄닌과 조합하여 인간 장 점막에 부착할 수 있는 능력을 가진 하나 이상의 락토바실러스 플랜타룸 또는 밀접하게 관련된 락토바실러스 종의 탄나아제-생성 스트레인을 포함하는 조성물.
- 제 1항에 있어서, 담체를 추가로 함유함을 특징으로 하는 조성물.
- 제 1항 또는 제 2항에 있어서, 식품 조성물임을 특징으로 하는 조성물.
- 제 1항 또는 제 2항에 있어서, 약제 조성물임을 특징으로 하는 조성물.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 락토바실러스 플랜타룸의 탄나아제-생성 스트레인을 포함함을 특징으로 하는 조성물.
- 오사와(Osawa) 및 왈쉬(Walsh)에 의해 기술된 방법에 의해 측정되었을 때 탄나아제 활성을 가짐을 특징으로 하는 인간 장내 점막에 부착될 수 있는 능력을 가지는 락토바실러스 플랜타룸 또는 밀접하게 관련된 락토바실러스 종의 탄나아제-생성 스트레인(락토바실러스 플랜타룸 299, DSM 6595, 및 락토바실러스 플랜타룸 299v, DSM 9843 스트레인에 대한 권리는 주장하지 않음).
- 제 6항에 있어서, 락토바실러스 플랜타룸 HEAL 9, DSM 15312, 또는 동일한 REA-패턴을 필수적으로 가지는 이들의 변이체임을 특징으로 하는 탄나아제-생성 스트레인.
- 제 6항에 있어서, 락토바실러스 플랜타룸 HEAL 19, DSM 15313, 또는 동일한 REA-패턴을 필수적으로 가지는 이들의 변이체임을 특징으로 하는 탄나아제-생성 스트레인.
- 제 6항에 있어서, 락토바실러스 플랜타룸 HEAL 99, DSM 15316, 또는 동일한 REA-패턴을 필수적으로 가지는 이들의 변이체임을 특징으로 하는 탄나아제-생성 스트레인.
- 탄닌과 조합하여 인간 장내 점막에 부착할 수 있는 능력을 가지는 락토바실러스 플랜타룸 또는 밀접하게 관련된 락토바실러스 종의 탄나아제 생성 스트레인의 심혈관 질환, 당뇨병, 염증성 장 질환(IBD), 과민성 장 증후군(IBS), 위장내 감염증, 암, 알츠하미어병 또는 자가면역 기원을 가지는 질환의 예방 또는 치료를 위한 약제 제조용 용도.
- 제 10항에 있어서, 탄나아제-생성 스트레인이 락토바실러스 플랜타룸 HEAL 9, DSM 15312, 락토바실러스 플랜타룸 HEAL 19, DSM 15313, 락토바실러스 플랜타룸 HEAL 99, DSM 15316, 및 동일한 REA-패턴을 필수적으로 가지는 이들의 변이체로 구성된 군으로부터 선택됨을 특징으로 하는 용도.
- 탄닌과 조합하여 인간 장내 점막에 부착할 수 있는 능력을 가지는 락토바실러스 플랜타룸 또는 밀접하게 관련된 락토바실러스 종의 탄나아제 생성 스트레인의 식품 보존용 용도.
- 제 12항에 있어서, 탄나아제 생성 스트레인이 락토바실러스 플랜타룸 HEAL 9, DSM 15312, 락토바실러스 플랜타룸 HEAL 19, DSM 15313, 락토바실러스 플랜타룸 HEAL 99, DSM 15316, 락토바실러스 플랜타룸 299v, DSM 9843 및 동일한 REA-패턴을 필수적으로 가지는 이들의 변이체로 구성된 군으로부터 선택됨을 특징으로 하는 용도.
- 탄닌과 조합하여 인간 장내 점막에 부착할 수 있는 능력을 가지는 락토바실러스 플랜타룸 또는 밀접하게 관련된 락토바실러스 종의 탄나아제-생성 스트레인의 신규한 식품 제조용 용도.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300994-1 | 2003-04-04 | ||
SE0300994A SE527555C2 (sv) | 2003-04-04 | 2003-04-04 | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
US46305803P | 2003-04-16 | 2003-04-16 | |
US60/463,058 | 2003-04-16 | ||
PCT/SE2004/000509 WO2004087893A1 (en) | 2003-04-04 | 2004-04-02 | Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060005356A true KR20060005356A (ko) | 2006-01-17 |
KR101122916B1 KR101122916B1 (ko) | 2012-06-13 |
Family
ID=20290933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057018900A KR101122916B1 (ko) | 2003-04-04 | 2004-04-02 | 탄닌과 배합된 락토바실러스 플랜타룸 균주를 포함하는 조성물 및 락토바실러스 플랜타룸 균주 |
Country Status (19)
Country | Link |
---|---|
US (3) | USRE44400E1 (ko) |
EP (2) | EP2163162B1 (ko) |
JP (1) | JP4731469B2 (ko) |
KR (1) | KR101122916B1 (ko) |
CN (2) | CN102210717B (ko) |
AT (1) | ATE546516T1 (ko) |
AU (1) | AU2004225568B2 (ko) |
BR (2) | BRPI0409206C1 (ko) |
CA (1) | CA2521220C (ko) |
DK (1) | DK1613740T3 (ko) |
ES (2) | ES2751101T3 (ko) |
HK (2) | HK1094004A1 (ko) |
PL (2) | PL2163162T3 (ko) |
PT (1) | PT1613740E (ko) |
RU (1) | RU2356942C2 (ko) |
SE (1) | SE527555C2 (ko) |
SI (1) | SI1613740T1 (ko) |
WO (1) | WO2004087893A1 (ko) |
ZA (1) | ZA200507938B (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110018898A (ko) * | 2008-05-13 | 2011-02-24 | 오위 테르비슬리쿠 피마 바이오테흐놀로지아테 아렌두스케스쿠스 | 자연 면역을 증가시키는 프로바이오틱인 단리된 락토바실러스 플란타룸 균주 인듀시아 dsm 21379와, 이를 포함하는 식품과 의약적 제제 |
WO2012169842A2 (ko) * | 2011-06-10 | 2012-12-13 | (주)아모레퍼시픽 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
KR101510691B1 (ko) * | 2007-03-01 | 2015-04-10 | 프로비 아베 | 박테리아 다양성을 증가시키는 락토바실러스 플란타룸의 용도 |
KR102390694B1 (ko) * | 2021-07-13 | 2022-04-29 | 한국식품연구원 | 락티플란티바실러스 파라플란타룸 WiKim0130을 포함하는 암의 예방, 개선 또는 치료용 조성물 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE528382C2 (sv) * | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
SE529199C2 (sv) * | 2005-07-05 | 2007-05-29 | Probi Ab | Förstärkt absorption |
WO2007009187A1 (en) * | 2005-07-22 | 2007-01-25 | Tarac Technologies Pty Ltd | Polyphenol and probiotic containing nutritional supplement |
EP3067057B1 (en) | 2005-09-28 | 2022-11-09 | Nordic Rebalance A/S | Probiotic fermented cereal compositions for use in treatment of gastrointestinal disorders caused by pro-inflammatory bacteria |
ES2460891T3 (es) * | 2005-10-06 | 2014-05-14 | Probi Ab | Uso de lactobacilus para el tratamiento de enfermedades autoinmunes |
US20080269142A1 (en) * | 2006-10-23 | 2008-10-30 | Ian Blair | Endogenous thiadiazabicyclo glutathione-adduct |
WO2008075949A1 (en) * | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms |
SE532899C2 (sv) * | 2007-06-08 | 2010-05-04 | Probi Ab | Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel |
BRPI0910839A2 (pt) * | 2008-04-30 | 2015-07-28 | Nestec Sa | Produtos contendo, e usos de, ácidos fenólicos descarboxilados derivados de ácidos clorogênicos de café |
EP2285230A1 (en) * | 2008-04-30 | 2011-02-23 | Nestec S.A. | Compositions for preparing a coffee beverage comprising hydrolysed chlorogenic acid |
EP2210505A1 (en) * | 2009-01-27 | 2010-07-28 | Nestec S.A. | Composition comprising caftaric acid and/or derivatives thereof |
EP2210504A1 (en) * | 2009-01-27 | 2010-07-28 | Nestec S.A. | Composition comprising chicoric acid and/or derivatives thereof |
JP2013507394A (ja) * | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
JP5932662B2 (ja) * | 2009-12-22 | 2016-06-08 | プロビ アクティエボラーグ | 穀物ベースフラクション及びプロバイオティックを含む非発酵組成物、並びにそれらの使用 |
TWI401086B (zh) * | 2010-07-20 | 2013-07-11 | Univ China Medical | 胚芽乳酸桿菌及其用途 |
ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
CN103173379A (zh) * | 2011-12-22 | 2013-06-26 | 熊津食品有限公司 | 新型的红参发酵用微生物,及其利用该微生物的红参发酵液和红参发酵饮料 |
TWI463986B (zh) | 2012-08-29 | 2014-12-11 | Univ China Medical | 胚芽乳酸桿菌cmu995菌株之新用途 |
AU2015341571A1 (en) * | 2013-11-05 | 2017-05-18 | Optibiotix Limited | Prebiotic composition and its method of production |
ES2764210T3 (es) | 2014-11-25 | 2020-06-02 | Dsm Ip Assets Bv | Lactobacillus para usar como probiótico |
RU2600445C1 (ru) * | 2015-09-21 | 2016-10-20 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) | Способ биоиндикации состояния двухстворчатых моллюсков в условиях техногенного загрязнения среды обитания |
GB201600975D0 (en) | 2016-01-19 | 2016-03-02 | Probi Ab | Novel strain of probiotic bacteria and compositions and uses thereof |
IT201700057079A1 (it) * | 2017-05-25 | 2018-11-25 | Probiotical Spa | Batterioterapia a base di composizioni batteriche per il trattamento di malattie neurodegenerative |
CA3102445A1 (en) * | 2018-06-18 | 2019-12-26 | Probi Ab | Lactobacillus plantarum compositions and uses thereof |
US11122828B2 (en) * | 2018-11-05 | 2021-09-21 | MarvelBiome, Inc. | Microbial compositions comprising ellagitannin and methods of use |
WO2020181096A1 (en) * | 2019-03-05 | 2020-09-10 | The Texas A&M University System | Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism |
GB201908154D0 (en) * | 2019-06-07 | 2019-07-24 | Probi Ab | Lactobacillus compositions and uses thereof |
CN111500655B (zh) * | 2020-03-19 | 2021-03-05 | 北京北农科技有限公司 | 一种五倍子单宁制备新工艺 |
CN112386614B (zh) * | 2020-11-25 | 2022-11-08 | 天津科技大学 | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 |
CN114107161B (zh) * | 2021-11-15 | 2023-06-20 | 泸州老窖股份有限公司 | 一种混合驯化菌株降解石榴皮生产鞣花酸的方法 |
CN113980858B (zh) * | 2021-11-18 | 2023-05-02 | 上海植酵盛生物科技有限公司 | 一株产高活性单宁酶的植物乳杆菌yl399及其在制备党参发酵饲料中的应用 |
CN117384879B (zh) * | 2023-01-13 | 2024-04-30 | 中国农业科学院茶叶研究所 | 一种适应茶汁体系的耐酸单宁酶制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2453763A1 (fr) | 1979-04-14 | 1980-11-07 | Teves Gmbh Alfred | Regulateur de force de freinage a deux circuits, comportant un piston d'arret actionnable hydrauliquement |
JPS5785326A (en) | 1980-11-14 | 1982-05-28 | Asahi Glass Co Ltd | Stabilization of flon |
JPS6425726A (en) | 1987-04-24 | 1989-01-27 | Yuutoku Yakuhin Kogyo Kk | Agent for eliminating active oxygen free radical |
SE463796B (sv) * | 1988-03-09 | 1991-01-28 | Carl Erik Albertsson | Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition |
SE469875C (sv) * | 1991-07-25 | 1997-02-05 | Probi Ab | Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen |
JP3459837B2 (ja) * | 1992-05-12 | 2003-10-27 | 太陽化学株式会社 | 生菌粉末 |
JP4127863B2 (ja) | 1993-03-04 | 2008-07-30 | 太陽化学株式会社 | 腸内環境改善組成物 |
SE9501056D0 (sv) * | 1995-03-23 | 1995-03-23 | Probi Ab | Epithelial adherent lactobacilli |
SE9501719D0 (sv) * | 1995-05-09 | 1995-05-09 | Probi Ab | Pharmaceutical composition |
SE510753C2 (sv) * | 1997-08-05 | 1999-06-21 | Probi Ab | Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod |
PL347029A1 (en) | 1998-10-01 | 2002-03-11 | Probi Ab | Reduction of oxidative stress factors |
FR2789580A1 (fr) * | 1999-02-12 | 2000-08-18 | Oreal | Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations |
SE523771C2 (sv) * | 1999-05-21 | 2004-05-18 | Probi Ab | Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller |
SE0004124D0 (sv) | 2000-11-10 | 2000-11-10 | Probi Ab | New use |
KR100549193B1 (ko) * | 2002-10-23 | 2006-02-02 | (주)바이오뉴트리젠 | 인삼 및 폴리페놀계 물질 또는 바이오플라보노이드계 물질을 포함하는 식물의 분말 또는 추출물을 포함하는 항비만용 식품 |
-
2003
- 2003-04-04 SE SE0300994A patent/SE527555C2/sv not_active IP Right Cessation
-
2004
- 2004-04-02 AT AT04725573T patent/ATE546516T1/de active
- 2004-04-02 DK DK04725573.2T patent/DK1613740T3/da active
- 2004-04-02 BR BRPI0409206A patent/BRPI0409206C1/pt active IP Right Grant
- 2004-04-02 US US13/070,715 patent/USRE44400E1/en not_active Ceased
- 2004-04-02 CN CN2011100607082A patent/CN102210717B/zh not_active Expired - Lifetime
- 2004-04-02 ZA ZA200507938A patent/ZA200507938B/en unknown
- 2004-04-02 PL PL09176668T patent/PL2163162T3/pl unknown
- 2004-04-02 EP EP09176668.3A patent/EP2163162B1/en not_active Expired - Lifetime
- 2004-04-02 AU AU2004225568A patent/AU2004225568B2/en not_active Expired
- 2004-04-02 WO PCT/SE2004/000509 patent/WO2004087893A1/en active Application Filing
- 2004-04-02 ES ES09176668T patent/ES2751101T3/es not_active Expired - Lifetime
- 2004-04-02 PT PT04725573T patent/PT1613740E/pt unknown
- 2004-04-02 US US13/910,278 patent/USRE46718E1/en active Active
- 2004-04-02 ES ES04725573T patent/ES2382930T3/es not_active Expired - Lifetime
- 2004-04-02 CN CN2004800153092A patent/CN1798831B/zh not_active Expired - Lifetime
- 2004-04-02 US US10/551,991 patent/US7507572B2/en not_active Ceased
- 2004-04-02 KR KR1020057018900A patent/KR101122916B1/ko active IP Right Grant
- 2004-04-02 CA CA2521220A patent/CA2521220C/en not_active Expired - Lifetime
- 2004-04-02 EP EP04725573A patent/EP1613740B1/en not_active Expired - Lifetime
- 2004-04-02 RU RU2005134223/13A patent/RU2356942C2/ru active
- 2004-04-02 BR BR122018068574-3A patent/BR122018068574B1/pt active IP Right Grant
- 2004-04-02 JP JP2006507999A patent/JP4731469B2/ja not_active Expired - Lifetime
- 2004-04-02 PL PL04725573T patent/PL1613740T3/pl unknown
- 2004-04-02 SI SI200431870T patent/SI1613740T1/sl unknown
-
2006
- 2006-12-27 HK HK06114164.5A patent/HK1094004A1/xx not_active IP Right Cessation
-
2012
- 2012-04-10 HK HK12103485.2A patent/HK1162937A1/xx not_active IP Right Cessation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101510691B1 (ko) * | 2007-03-01 | 2015-04-10 | 프로비 아베 | 박테리아 다양성을 증가시키는 락토바실러스 플란타룸의 용도 |
KR20110018898A (ko) * | 2008-05-13 | 2011-02-24 | 오위 테르비슬리쿠 피마 바이오테흐놀로지아테 아렌두스케스쿠스 | 자연 면역을 증가시키는 프로바이오틱인 단리된 락토바실러스 플란타룸 균주 인듀시아 dsm 21379와, 이를 포함하는 식품과 의약적 제제 |
WO2012169842A2 (ko) * | 2011-06-10 | 2012-12-13 | (주)아모레퍼시픽 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
WO2012169842A3 (ko) * | 2011-06-10 | 2013-03-07 | (주)아모레퍼시픽 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
US9782446B2 (en) | 2011-06-10 | 2017-10-10 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US9889167B2 (en) | 2011-06-10 | 2018-02-13 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US9895402B2 (en) | 2011-06-10 | 2018-02-20 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US9895401B2 (en) | 2011-06-10 | 2018-02-20 | Amorepacific Corporation | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
KR102390694B1 (ko) * | 2021-07-13 | 2022-04-29 | 한국식품연구원 | 락티플란티바실러스 파라플란타룸 WiKim0130을 포함하는 암의 예방, 개선 또는 치료용 조성물 |
WO2023287202A1 (ko) * | 2021-07-13 | 2023-01-19 | 한국식품연구원 | 락티플란티바실러스 파라플란타룸 wikim0130을 포함하는 암의 예방, 개선 또는 치료용 조성물 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101122916B1 (ko) | 탄닌과 배합된 락토바실러스 플랜타룸 균주를 포함하는 조성물 및 락토바실러스 플랜타룸 균주 | |
US20100291050A1 (en) | Nutritional Compositions for Reducing Oxidative Damage | |
KR20110000871A (ko) | 항산화 및 항염증 효능을 갖는 락토바실러스 플란타룸 에이취와이7711 및 이를 유효성분으로 함유하는 제품 | |
US20210275601A1 (en) | Ldl-cholesterol-lowering cell extract and food supplement | |
KR20080075971A (ko) | 프로바이오틱스 복합 제제 | |
KR101190901B1 (ko) | 바실러스 서브틸리스 csy191 균주 및 이를 포함한 생균제제 | |
KR20090116051A (ko) | 대장염 발생 예방 효능을 가진 락토바실러스 브레비스에이치와이7401 및 이를 유효성분으로 함유하는 제품 | |
KR20010075495A (ko) | 산화성 스트레스 인자의 감소 | |
KR102232341B1 (ko) | 박하잎 및 생강의 발효물을 유효성분으로 함유하는 피부노화 또는 피부염증의 예방 또는 개선용 화장료 조성물 | |
KR101266328B1 (ko) | 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 가세리 에이치와이7021 및 이를 유효성분으로 함유하는 제품 | |
KR20130079146A (ko) | 아토피성 피부염 개선제 조성물 | |
KR20120137127A (ko) | 차 추출물 및 유산균을 포함하는 조성물 | |
KR960009004B1 (ko) | 셀레늄 함유 유산균 식품 및 그의 제조방법 | |
KR100527103B1 (ko) | 지질대사개선효능을 갖는 미생물을 함유한 성인병 예방 및치료용 조성물 및 이의 용도 | |
KR20060128125A (ko) | 만델산을 유효성분으로 함유하는 질염 치료제 | |
KR101427830B1 (ko) | 프로바이오틱스 유산균을 활용한 발효유 제조방법 | |
KR100630907B1 (ko) | 락토바실러스 스포러제네스 씨유 4109 | |
KR20220109664A (ko) | 피부 염증의 예방 또는 개선 효과를 갖는 바실러스 리체니포미스 및 이의 용도 | |
KR20200023123A (ko) | 락토바실러스 속 균주의 배양물 및 티몰을 포함하는 항암용 조성물 및 그 제조 방법 | |
KR20050105313A (ko) | 비피더스-효모 혼합 발효음료 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150211 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160128 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170202 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180125 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190222 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200203 Year of fee payment: 9 |